What Challenges are Involved in the Bench-to-Bedside Process?
The bench-to-bedside process is complex and faces several challenges:
Scientific Complexity: Cancer is a highly heterogeneous disease with multiple subtypes, making it challenging to identify universal targets and treatments. Translational Gaps: Findings from preclinical studies do not always translate effectively to human patients, necessitating further research and adjustments. Regulatory Hurdles: Obtaining regulatory approval involves stringent requirements and extensive documentation, which can be time-consuming and costly. Financial Constraints: The development of new cancer therapies requires significant financial investment, and funding can be a limiting factor. Ethical Considerations: Clinical trials must adhere to ethical guidelines to ensure patient safety and informed consent.
